Novartis AG (NVS)
| Market Cap | 227.02B |
| Revenue (ttm) | 55.19B |
| Net Income (ttm) | 13.65B |
| Shares Out | 1.94B |
| EPS (ttm) | 6.85 |
| PE Ratio | 16.63 |
| Forward PE | 13.74 |
| Dividend | $2.60 (2.23%) |
| Ex-Dividend Date | Mar 12, 2025 |
| Volume | 1,415,128 |
| Open | 117.18 |
| Previous Close | 117.22 |
| Day's Range | 116.30 - 117.61 |
| 52-Week Range | 96.06 - 124.83 |
| Beta | 0.53 |
| Analysts | Hold |
| Price Target | 123.67 (+6.04%) |
| Earnings Date | Jul 17, 2025 |
About NVS
Novartis AG engages in the research, development, manufacture, distribution, marketing, and sale of pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor for the treatment of symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Re... [Read more]
Financial Performance
In 2024, Novartis AG's revenue was $51.72 billion, an increase of 10.85% compared to the previous year's $46.66 billion. Earnings were $11.94 billion, a decrease of -19.59%.
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for NVS stock is "Hold." The 12-month stock price target is $123.67, which is an increase of 6.04% from the latest price.
News
3 Pharma Stocks That Aren't Sweating the Coming 200% Drug Tariffs
On July 8, US President Donald Trump shook the biopharmaceutical sector by announcing a tariff of up to 200% on pharmaceuticals, which would take effect “very soon.” 80% of prescription drugs sold in ...
Novartis to pay Matchpoint up to $1 billion to develop anti-inflammatory therapies
Swiss drugmaker Novartis will pay up to $1 billion to U.S. biotech Matchpoint Therapeutics to develop oral drugs for several inflammatory diseases.
Matchpoint Therapeutics Announces Exclusive Option and License Agreement with Novartis to Develop Oral Inhibitors for Multiple Inflammatory Diseases
Matchpoint to receive up to $60 million in upfront payment and research funding, with up to $1 billion in total potential payments, including option exercise fee, development and commercial milestones...
Novartis AG (NVS) Q2 2025 Earnings Call Transcript
Novartis AG (NYSE:NVS) Q2 2025 Earnings Conference Call July 17, 2025 8:00 AM ET Company Participants Harry Kirsch - Chief Financial Officer Sloan Simpson - Global Head of Investor Relations Vasant N...
Novartis CEO: We're in open discussions with the Trump administration
Novartis CEO Vas Narasimhan said Thursday that the company is in open discussions with the Trump administration over pharmaceutical tariffs, aiming to strike a balance between lowering patient costs a...
Tariffs are an overhang on pharma sector, but we will comeback, says Novartis CEO Vas Narasimhan
Vas Narasimhan, Novartis CEO, joins 'Money Movers' to discuss tariffs on pharmaceuticals, second quarter earnings and outlook on the pharma sector.
Novartis: Q2 Earnings Review - Solid Results Justify All-Time High Share Price
Novartis AG delivered strong Q2 2025 results, outpacing expectations, but faces looming patent expiries for major drugs like Entresto, Tasigna, and Promacta. Growth in new and existing pipeline drugs,...
Novartis raises outlook on strong second-quarter sales
CNBC's Karen Gilchrist weighs in on Novartis' second-quarter earnings and efforts to diversify its drug portfolio beyond its blockbuster Entresto heart failure treatment.
Swiss pharma giant Novartis bets on a breast cancer blockbuster as sales rise
Novartis said Thursday that it expects its Kisqali breast cancer treatment to be the next blockbuster drug within its portfolio. The Swiss pharma firm is looking to shift reliance away from its Entres...
Novartis lifts full-year profit forecast, announces $10 billion share buyback
Swiss pharmaceutical giant Novartis has raised its full-year earnings forecast, citing robust revenue growth from key products, including its breast cancer drug Kisqali, during a strong second quarter...
Novartis slightly raises 2025 earnings forecast, citing strong Q2
Novartis on Thursday posted a slightly more optimistic full-year earnings forecast, citing the strong growth of drugs such as breast cancer drug Kisqali during the second quarter.
Novartis Appoints Mukul Mehta as Chief Financial Officer, as Harry Kirsch Retires after 22 Years with the Company
Ad hoc announcement pursuant to Art. 53 LR Mukul Mehta, currently Head of Business Planning and Analysis (BPA), Digital Finance and Tax, has been appointed Chief Financial Officer, effective March 16,...
Novartis reports strong Q2 with double-digit sales growth and core margin expansion; raises FY 2025 core operating income guidance
Ad hoc announcement pursuant to Art. 53 LR Q2 net sales grew +11% (cc 1 , +12% USD) with core operating income 1 up +21% (cc, +20% USD) Sales growth driven by continued strong performance from Kisqali...
Novartis cannot block generic version of Entresto, judge rules
A federal judge rejected Novartis' request for a preliminary injunction to stop MSN Pharmaceuticals from selling a generic version of the blockbuster heart medication Entresto.
Why Novartis Is Still A 'Buy' After 15% Surge
Despite Trump's hot take toward the pharmaceutical industry and his hard stance on U.S. trading partners, Novartis' share price continues to rise. The main contributors to maintaining bullish sentimen...
Novartis loses bid to block US Entresto generic through 2026
Novartis cannot block drugmaker MSN Pharmaceuticals from launching a generic version of its blockbuster heart-failure drug Entresto through late 2026, a Delaware federal judge said on Friday.
Novartis gets approval for first malaria drug for babies and children
Novartis on Tuesday said it had received approval in Switzerland for Coartem, which it said was the first drug to treat malaria in babies and young children.
Novartis receives approval for first malaria medicine for newborn babies and young infants
Basel, July 8, 2025 – Novartis today announced Coartem® (artemether-lumefantrine) Baby has been approved by Swissmedic as the first malaria medicine for newborns and young infants. The new treatment, ...
Novartis drug Cosentyx fails late-stage trial for artery disease
Novartis said on Thursday that its Cosentyx drug had failed in a late-stage trial on adults with giant cell arteritis (GCA), a condition characterised by inflammation of the arteries.
Novartis provides update on Phase III GCAptAIN study of Cosentyx® in giant cell arteritis (GCA)
The GCAptAIN study did not meet its primary endpoint of sustained remission at Week 52 in adults with newly diagnosed or relapsing GCA1 Safety in GCA patients was consistent with known safety profile ...
Final Trades: Novartis, Sixth Street, Amazon and the IYF
The Investment Committee give you their top stocks to watch for the second half.
ProFound Therapeutics Announces Multi-Year Strategic Collaboration with Novartis to Discover and Develop Novel Therapeutics for Cardiovascular Disease
ProFound to receive $25M in upfront and near-term milestone payments with a potential value from downstream milestones of $750M per target
Novartis completes acquisition of Regulus Therapeutics
Basel, June 25, 2025 – Novartis today announced that it has successfully completed its acquisition of Regulus Therapeutics Inc. (“Regulus”). With the completion of the acquisition, shares of common st...
Novartis: A SWAN Worth Owning
Novartis AG could be a qualitative investment with a margin of safety. The drugmaker arguably has the balanced commercial drug portfolio and drug pipeline needed to sustain growth in the years ahead. ...
Novartis announces expiration of Regulus Therapeutics tender offer
Basel, June 25, 2025 – Novartis today announced that its previously announced tender offer (the “Offer”) by Redwood Merger Sub Inc., a Delaware corporation and an indirect wholly owned subsidiary of N...